Cytion

Cytion

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Cytion operates as a trusted supplier of authenticated cell lines and cell culture services, catering primarily to academic, biotech, and pharmaceutical researchers. The company differentiates itself through a stringent quality assurance process, guaranteeing cells free from mycoplasma and cross-contamination, and a flexible, customer-centric business model with tailored pricing for commercial and non-profit entities. With a portfolio of over 800 cell lines and services like cell banking and assay-ready cells, Cytion is positioned as a critical infrastructure provider supporting foundational biomedical research and drug discovery.

OncologyImmunology

Technology Platform

A rigorous quality control and authentication platform for biological materials, including cell line authentication, contamination screening (mycoplasma, viruses), and expertise in cell culture expansion and banking.

Opportunities

Growing demand for authenticated cell lines due to increased focus on research reproducibility, and the expansion of the cell therapy and biologics R&D sector which relies on high-quality starting materials.
The trend towards outsourcing routine lab work also benefits its service offerings.

Risk Factors

Faces intense competition from large, established life science suppliers.
Operational risks include supply chain disruptions or quality control failures that could damage its reputation.
Revenue is sensitive to fluctuations in biotech funding and academic research budgets.

Competitive Landscape

Cytion competes in the research cell market against giants like ATCC and MilliporeSigma, as well as numerous niche providers. It differentiates through a strong focus on authentication, contamination-free guarantees, and a customer-centric pricing model tailored for both commercial and non-profit entities.